Understanding how RNA changes drive breast cancer spread
The RNA structural code underlying pathological regulation of RNA splicing in metastasis
This project aims to uncover new ways that RNA changes contribute to breast cancer spreading, which could lead to new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11118673 on NIH RePORTER |
What this research studies
We know that abnormal changes in RNA, called splicing, are common in cancer and can help tumors grow. However, we don't fully understand how these changes happen or how much they affect cancer spreading. This project uses a special computer method to find new ways that RNA is regulated, focusing on its structure, not just its sequence. We have already found a new RNA pathway that drives breast cancer spread in lab models and is linked to worse outcomes in patients.
Who could benefit from this research
Good fit: This foundational research is focused on understanding the biology of breast cancer metastasis, and while not directly recruiting, it is highly relevant to patients with metastatic breast cancer.
Not a fit: Patients without breast cancer or those whose cancer does not involve the specific RNA pathways being studied may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could identify new targets for drugs to stop breast cancer from spreading, potentially improving treatment options for patients with metastatic disease.
How similar studies have performed: While the specific RNA structural enhancer discovered is novel, the broader approach of studying RNA splicing in cancer has shown promise in other research efforts.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Goodarzi, Hani — University of California, San Francisco
- Study coordinator: Goodarzi, Hani
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.